09:47 AM EST - YM BioSciences Inc. : reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients. YM BioSciences Inc.
shares T.YM are trading down $0.04 at $2.00.
